Literature DB >> 11106247

FRA-1 expression in hyperplastic and neoplastic thyroid diseases.

G Chiappetta1, G Tallini, M C De Biasio, F Pentimalli, F de Nigris, S Losito, M Fedele, S Battista, P Verde, M Santoro, A Fusco.   

Abstract

fra-1 gene overexpression has been shown to represent a general event in thyroid cell transformation in vitro and in vivo. Moreover, inhibition of FRA-1 protein synthesis by stable transfection with a fra-1 antisense construct significantly reduces the malignant phenotype of the transformed thyroid cells, indicating a pivotal role of the fra-1 gene product in the process of cellular transformation. In the attempt to define the potential use of FRA-1 protein detection in the diagnosis of thyroid diseases, we analyzed Fra-1 expression by a combination of immunohistochemistry and reverse transcription-PCR (RT-PCR) assay in 174 samples of thyroid nodules (22 nodular hyperplasias, 102 follicular adenomas, 34 papillary carcinomas, 12 follicular carcinomas, and 4 anaplastic carcinomas) representative of the spectrum of thyroid tumor pathology. FRA-1 protein was abundant in all of the carcinoma samples (50/50, 100%), with an intense staining in the nucleus and the cytoplasm. Positive staining was also found in most of the adenomas (90 of 102; 88%), but in this case, the staining was restricted to the nucleus. Similar results were obtained from the analysis of thyroid goiters; however, the number of positive cases is lower than adenomas (8 of 22; 36%); moreover, the staining was not observed in all of the cells. Conversely, no FRA-1 protein was detectable in 12 normal thyroid tissue samples used as controls. RT-PCR analysis confirmed a higher fra-1 expression in papillary and follicular carcinomas compared with goiters and adenomas. fra-1 expression was also analyzed on 10 fine needle aspiration biopsy (FNAB) samples by RT-PCR. fra-1-specific mRNA was detected in seven of the eight FNABs corresponding to thyroid nodules that were eventually diagnosed as adenomas (three of four) and carcinomas (four of four) after surgery. Conversely, no fra-1 gene expression was observed in two FNABs derived from normal thyroid. Further studies are required before suggesting FRA-1 protein detection as a useful tool for the diagnosis of hyperplastic and neoplastic disorders of the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106247

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

Review 1.  Our approach to follicular-patterned lesions of the thyroid.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

2.  Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties.

Authors:  L Oliveira-Ferrer; M Kürschner; V Labitzky; D Wicklein; V Müller; G Lüers; U Schumacher; K Milde-Langosch; C Schröder
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-10       Impact factor: 4.553

Review 3.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

4.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma.

Authors:  Flavia R R Mangone; M Mitzi Brentani; Suely Nonogaki; Maria Dirlei F S Begnami; Antonio Hugo J F M Campos; Fernando Walder; Marcos B Carvalho; Fernando A Soares; Humberto Torloni; Luiz P Kowalski; Miriam H H Federico
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

6.  HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.

Authors:  Maria E Ramos-Nino; Steven R Blumen; Tara Sabo-Attwood; Harvey Pass; Michele Carbone; Joseph R Testa; Deborah A Altomare; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2007-09-13       Impact factor: 6.914

7.  PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.

Authors:  Wenjuan Li; Joan Liu; Yunfeng Zhao
Journal:  Mol Carcinog       Date:  2012-12-19       Impact factor: 4.784

Review 8.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

9.  Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine.

Authors:  Yunping Luo; He Zhou; Masato Mizutani; Noriko Mizutani; Ralph A Reisfeld; Rong Xiang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-11       Impact factor: 11.205

10.  Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization.

Authors:  Laura Casalino; Dario De Cesare; Pasquale Verde
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.